PharmaTher Holdings Ltd PHRRF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PHRRF is a good fit for your portfolio.
News
-
PharmaTher’s Sairiyo Therapeutics Submits Clinical Trial Application for Phase 1 Study of Patented Reformulated Cepharanthine
-
PharmaTher Announces Assigned FDA Approval Goal Date of its Priority Original Abbreviated New Drug Application for Ketamine
-
PharmaTher’s Sairiyo Therapeutics Completes Clinical and Regulatory Package for Phase 1 Study of Patented Reformulated Cepharanthine
-
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
-
PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
-
Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
-
PharmaTher’s Sairiyo Therapeutics Inc. Advances Clinical Development of Patented Reformulated Cepharanthine for Phase 1 Study in Australia
Trading Information
- Previous Close Price
- $0.16
- Day Range
- $0.16–0.18
- 52-Week Range
- $0.06–0.32
- Bid/Ask
- $0.16 / $0.17
- Market Cap
- $14.53 Mil
- Volume/Avg
- 132,226 / 645,696
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PharmaTher Holdings Ltd is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals for FDA approval to treat mental health, neurological, and pain disorders. Its product pipeline includes Ketamine, KETABET, Microneedle Patch among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- —
- Website
- https://www.pharmather.com
Valuation
|
Metric
|
PHRRF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PHRRF
|
|---|---|
Quick Ratio | 6.08 |
Current Ratio | 6.08 |
Interest Coverage | — |
Quick Ratio
PHRRF
Profitability
|
Metric
|
PHRRF
|
|---|---|
Return on Assets (Normalized) | −72.24% |
Return on Equity (Normalized) | −1,118.34% |
Return on Invested Capital (Normalized) | −86.80% |
Return on Assets
PHRRF
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Nywbwzdhj | Qjcd | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Pnnhcytf | Ryvjx | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Hglnlwzw | Kkqvlm | $106.7 Bil | |
MRNA
| Moderna Inc | Ckhlnwkzx | Tkm | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Dwfdkvjc | Ycxcl | $22.4 Bil | |
ARGX
| argenx SE ADR | Jbgdhybbc | Bdpxt | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Gzrryvt | Cdgtvw | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Fqdltpzy | Vqbwqg | $14.6 Bil | |
INCY
| Incyte Corp | Rkqpmqsk | Tppzl | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rsmlfybxg | Zzdqnlk | $12.6 Bil |